MELBOURNE, Australia, June 21, 2018 — Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus™ mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD). [Read more…]
A Complete Guide to Induced Pluripotent Stem Cell (iPSC) Core Facilities
What Are Induced Pluripotent Stem Cell (iPSC) Core Facilities?
Induced pluripotent stem cell (iPSC) core facilities are facilities created to facilitate the derivation and distribution of induced pluripotent stem cell lines. These facilities promote iPSC research advances by providing disease-specific iPSC lines to researchers, thereby allowing more researchers to study mechanisms of disease and new therapeutic applications.
Induced pluripotent stem cell core facilities can also provide services related to iPSCs, including consultation and technical services, as well as training in iPSC technology. Common services that the core facilities provide are derivation, maintenance, and characterization of iPSCs. They may also provide control iPSC lines, validated iPSC culture reagents, and more.
FUJIFILM CDI Partners with UC Irvine to Commercialize iPSC-derived Microglia & Media
FUJIFILM Cellular Dynamics licenses University of California – Irvine’s technologies for derivation of microglia
MADISON, Wis., June 6, 2018 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, announced today that it has entered into an exclusive patent license agreement with the University of California – Irvine (UCI) through its offices at UCI Applied Innovation to license and commercialize UCI’s technologies for derivation of microglia in the commercial research field and also a non-exclusive patent license agreement to commercialize microglia media formulation. [Read more…]
Mesoblast & Cartherics to Produce Allogeneic CAR-T Cells from Gene-Edited iPS Cells
Mesoblast Partners With Cartherics to Develop ’off-the-shelf’ Cell-based Immunotherapies for Solid Cancers
Relapsed Ovarian and Gastric Cancers Initial Targets for Allogeneic CAR-T Cells
NEW YORK and MELBOURNE, Australia, May 29, 2018 — Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR-T cells armed with multiple targeting receptors for use in solid cancers. Off the shelf CAR-T therapies have the potential to reduce costs dramatically and open up this very effective treatment to millions of cancer patients across the world. The initial targets are relapsed ovarian and gastric cancers. Mesoblast and Cartherics will jointly own the intellectual property produced using their combined technologies. [Read more…]
World’s First Clinical Application of iPS Cells for Cardiac Disease
On 16 May, Nature News reported that “Japan’s health ministry gave doctors at Osaka University permission to take sheets of tissue derived from iPS cells and graft them onto diseased human hearts.” The team of Japanese doctors, led by cardiac surgeon Yoshiki Sawa at Osaka University, will use iPS cells to “create a sheet of 100 million heart-muscle cells.”
From preclinical studies in pigs, the team determined that thin sheets of cell grafts can improve heart function, likely through paracrine signalling. Paracrine signalling is a type of cell-to-cell communication through which cells “talk” to one another, often regulating inflammation, fibrosis (scarring), and and cellular recovery.
While the treatment will only be tested in three patients, a follow-up trial could enroll ten or more patients. Under Japan’s accelerated regulatory pathway for regenerative medicines (cell, gene and tissue products), Dr. Sawa’s iPS cell therapy could be conditionally marketed to the public if a follow-up trial demonstrated safety and an initial proof of efficacy.
Launched in late 2014, Japan’s fast-track system allows for regenerative therapies to receive conditional marketing authorization for up to 7 years, following confirmation of safety and an initial proof of efficacy in Japan in diseases that are serious and have a high unmet need. [Read more…]
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 68
- Next Page »